NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Clinical Trial Information
Trial Contact: Cevallos, Claudia; El-Shami, Jessica; Leffin, Melissa; Spinelli, Jennifer
IRB No: APEC1621SC
Protocol Abbrev: APEC1621SC
Principal Investigator: Amy A Smith, MD
Phase: Drug: Phase II
Age Group: Adult;Pediatric
Secondary Protocol No: APEC1621SC
Treatment: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Mutation Carrier Screening
ClinicalTrials.gov ID: NCT03155620
I. To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders.
II. To determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs.
III. To determine the objective response rates (ORR; complete response + partial response) in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders harboring a priori specified genomic alterations treated with pathway-targeting agents.
Sexes Eligible for Study - All
Ages - 12 Months to 21 Years (Child, Adult)
Accepts Healthy Volunteers - No